SCOPE 2023: Synopsis of Biospecimen Sample Management Presentation
Hope Meely, chief clinical officer at Slope, provides a brief summary of her SCOPE presentation revolving around biospecimen collection.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, explains why biospecimens within the precision and personalized medicine spaces have become so valuable. Meely is coming off her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?”
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.
